BOSTON (October 22, 2007) Researchers at Tufts University School of Medicine in collaboration with the Virginia Bioinformatics Institute at Virginia Tech have created a computer program called Pathogen Simulation (PathSim) to study the progression of Epstein-Barr virus (EBV) in humans. David Thorley-Lawson, PhD, professor of pathology at Tufts University School of Medicine, is combining PathSim, laboratory methods, and clinical studies to provide a new and powerful approach to understanding EBV and ultimately designing anti-viral therapies.
PathSim is an agent-based computer program. The agents are the virus itself, and the T and B cells of the patients immune system, explains Thorley-Lawson. Using PathSim, Thorley-Lawson can manipulate these agents to simulate EBV infection and persistence in humans. EBV can infect one person and remain latent not cause any symptoms. It can infect another person and cause infectious mononucleosis, or, in rare cases, cancer, like Hodgkins, Burkitts, and immunoblastic lymphomas, says Thorley-Lawson.
Scientists can use PathSim like a video game and change variables, such as number of virus particles or characteristics of the patients immune cells, to follow the course of disease and observe what drives the virus to either latency or illness.
We validated PathSim by comparing it to EBV infection in patients, says Thorley-Lawson. For example, PathSim projected that the peak in the number of infected immune cells, called B cells, would occur 33 through 38 days post-infection, which is consistent with the peak of 35 through 50 days actually seen in infected patients. This consistency is important because it validates the predictive power of PathSim; the power to reveal what EBV is doing in a patients body, says Thorley-Lawson.
It takes one full week to run one simulation, says Thorley-Lawson. Then we compile the data and look for critical switch points of disease. A switch point is a small change in the behavior of an agent that can influence the progression of disease. Such a change may determine whether the virus persists in the body in a latent state, or causes illness and even death by replicating out of control. Once these critical switch points are understood, biologists may be able to develop drugs that target specific points in the interaction between the virus and immune system at specific times, explains Thorley-Lawson. The more targeted the drug, the more safe and effective the resulting therapy. We hope that this marriage of computers and biology will eventually lead to better patient treatment against EBV.
|Contact: Siobhan Gallagher|
Tufts University, Health Sciences